Replies to post #1982788 on MOMO'S BREAKOUT BOARD

[BottomBounce]

$TYME $1.19 pps. a clinical-stage biotechnology company, develops cancer metabolism-based therapies in the United States. Its lead candidate is the SM-88, a CMBT that is in Phase II clinical trials to treat cancer, including pancreatic, lung, breast, prostate, and sarcoma cancers